Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

One-Compartment Open Model for Extravascular Administration: First-Order Absorption Model01:15

One-Compartment Open Model for Extravascular Administration: First-Order Absorption Model

310
The first-order absorption model for extravascular administration describes the rate at which a drug is absorbed and eliminated, following the principles of first-order kinetics. This model is vital as it provides a mathematical representation of drug behavior within the body. It also allows for the prediction and interpretation of drug absorption and elimination based on the rate of change in drug concentration over time. This model can be visualized as a plasma concentration-time profile...
310
One-Compartment Open Model for Extravascular Administration: Zero-Order Absorption Model01:12

One-Compartment Open Model for Extravascular Administration: Zero-Order Absorption Model

179
Extravascular administration, such as oral or intramuscular routes, is a non-invasive drug delivery method, often preferred for ease and patient compliance. A key factor here is absorption, which dictates how quickly and effectively the drug enters the bloodstream from the administration site. Absorption follows either zero-order or first-order kinetics.
Zero-order absorption maintains a steady rate irrespective of the amount of drug left to be absorbed, making it a constant process. In the...
179
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

88
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
88
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.2K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.2K
One-Compartment Open Model for IV Bolus Administration: General Considerations01:19

One-Compartment Open Model for IV Bolus Administration: General Considerations

333
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
333
Factors Influencing Drug Absorption: Drug Dissolution01:27

Factors Influencing Drug Absorption: Drug Dissolution

734
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
734

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Lexical Frequency Within Grammatical Bounds: Phonological Default and Inflection-Class Conditioning in Greek Nominal Stress.

Language and speech·2026
Same author

The top-down Physiologically Based Finite Time Pharmacokinetic (PBFTPK) models open a new avenue for early drug development.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026
Same author

Assessing the Potential of Generative Artificial Intelligence Models to Assist Experts in the Development of Pharmacokinetic Models.

Advanced pharmaceutical bulletin·2025
Same author

In-silico structural and functional analysis of nonsynonymous single nucleotide polymorphisms in human <i>FOLH1</i> gene.

In silico pharmacology·2025
Same author

FDA and EMA Oversight of Disruptive Science on Application of Finite Absorption Time (F.A.T.) Concept in Oral Drug Absorption: Time for Scientific and Regulatory Changes.

Pharmaceutics·2024
Same author

Architectural design of national evidence based medicine information system based on electronic health record.

Technology and health care : official journal of the European Society for Engineering and Medicine·2024

相关实验视频

Updated: Sep 19, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.1K

有限吸收时间概念指导模型 临床药理学中药物和仿制药的发展.

Panos Macheras1,2, Athanasios A Tsekouras3,4, Sergio Sánchez-Herrero5,6

  • 1Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece. macheras@pharm.uoa.gr.

Pharmaceutical research
|June 5, 2025
PubMed
概括

有限吸收时间 (F.A.T.) 该概念为药物和仿制药开发的药物动力学分析提供了更高的准确性. 这种方法增强了药物评估,并指导了监管战略.

关键词:
生物等价性 生物等价性有限的吸收时间.IVIVC IVIVC IVIVC IVIVC IVIVC IVIVC IVIVC IVIVC IVIVC IVIVC IVIVC IVIVC IVIVC IVIVC IVIVC IVIVC IVIVC IVIVC IVIVC IVIVC口服药物是一种药物.药理动力学 药理动力学基于生理学的有限时间药理动力学模型.

更多相关视频

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
11:07

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging

Published on: November 24, 2021

2.9K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.0K

相关实验视频

Last Updated: Sep 19, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.1K
Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
11:07

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging

Published on: November 24, 2021

2.9K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.0K

科学领域:

  • 药理动力学 药理动力学
  • 药物开发 药物开发
  • 监管科学 监管科学

背景情况:

  • 传统的药理动力学模型在某些吸收场景中可能缺乏精度.
  • 有限吸收时间 (F.A.T.) 这一概念为分析药物吸收提供了一种新的方法.
  • 评估现有的药物开发和通用评估框架至关重要.

研究的目的:

  • 为了证明结合有限吸收时间 (F.A.T.) 的影响. 这个概念进入了药物开发中.
  • 探索对仿制药开发和评估的影响.
  • 检查相关的监管考虑因素.

主要方法:

  • 重新分析现有的药理动力学数据.
  • 使用基于有限吸收时间 (F.A.T.) 的模型. 一个原则. 一个原则.
  • 将基于FAT的新型指标与传统的吸收指标进行比较.

主要成果:

  • 从F.A.T.中获得的吸收指标. 与较旧的方法相比,模型显示出更高的准确性.
  • 这就是F.A.T. 这种方法可以更精细地评估药物吸收特征.
  • 在使用F.A.T.的药理动力学数据分析中观察到明显的优势. 模型. 模型.

结论:

  • 这就是F.A.T. 该概念及其相关的方法适用于药物和仿制药开发的所有阶段.
  • 这些方法可以为药物开发中的战略调整提供信息.
  • 这些发现表明,对药物评估的监管框架进行可能的修改.